Trials / Terminated
TerminatedNCT02601378
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LXS196 | LXS196 as a single agent |
| DRUG | LXS196 and HDM201 | LXS196 in combination with HDM201 |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2022-01-07
- Completion
- 2022-01-07
- First posted
- 2015-11-10
- Last updated
- 2022-09-29
Locations
6 sites across 6 countries: United States, Australia, France, Netherlands, Norway, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02601378. Inclusion in this directory is not an endorsement.